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1. Introduction 
The nicotinic acetylcholine receptor (AChR) is a 
major autoantigen i the neuromuscular disease 
myasthenia gravis (MG) and experimental utoimmune 
myasthenia gravis (EAMG) [l-3]. Cellular and 
humoral immune responses to AChR have been 
demonstrated in both the human and the xperimental 
diseases [I ,2,4-71. The involvement of anti-acetyl- 
choline receptor antibodies in the pathogenesis of 
MG and EAMG has been proposed on clinical and 
experimental ground. Passive transfer of immuno- 
globulins from myasthenic patients [8] and from 
animals with EAMG [9] resulted in my~~enia gravis- 
like symptoms. 
AChR is a complexed multideterminant immunogen 
which raises a heterogeneous immune response. In 
order to analyze the structure of the AChR molecule 
and for identifying the molecular entity which governs 
its myasthenic a tivity, large quantities of antibodies 
with defined specificity are required. Such antibodies 
also provide a useful tool for study~g the role of 
antibodies in myasthenia nd their mechanism of
action, To this end we have used the method of 
lymphocyte hybridization developed [lo]. Here we 
describe the preparation of monoclonal anti-AChR 
antibodies with restricted specificity towards defined 
determinants, secreted by hybridomas obtained by 
hybridi~tion of anti-AC!hR antibodies producing 
cells with a myeloma line. 
2. Materials and methods 
AChR was isolated from the electric organ of 
Torpedo califomica (pacific Bio-Marine, Venice, CA) 
ElsevierfNorth-Holland Biomedical Press 
and was purified as in [I I]. Reduced carboxy- 
methylated AChR (RCM-AChR) was prepared by 
reduction and carboxymethylation f AChR in 6 M 
guanidine-HCl [ 121. Trypsin-digested AChR prepara- 
tion (T-AChR) was prepared as in [ 131. cr-Bungarotoxin 
(o-Bgt) was prepared according to [ 141. Iodination of 
proteins with iasI was performed by the c~ora~ne-T 
method [15]. 
C57BL/6J mice were injected twice each with IO pg 
Triton-solubilized AChR [ 161. Sera of these mice 
contained high titers of anti-AChR antibodies (logs 
hemagglutination titer 1 O-l 6). In order to enrich the 
number of the specific antibody forming cells, 40 X lo6 
splenic cells of 2 mice e~ibiting muscular weakness 
characteristic to EAMG were transferred into lethally 
irradiated (800 R) syngeneic mice. Following cell 
transfer, the recipient mice were i.p. injected with 
10 pg purified AChR. The spleens of the recipient 
mice were removed 5 days later, and fused with the 
P3-NSI/l-Ag4-1 (NSI) non-secreting plasmacytoma, 
in the presence of polyethylene glycol as in [ 171. 
Anti-AChR ~tibody activity was tested in cultures 
exhibiting hybrid celI growth. The positive hybrid 
lines were further propagated in vitro and could 
develop antibody producing tumors upon i.p. inocula- 
tion into (C57BL/6 X BALB/c)Fl mice. Ascitic fluids 
developed in such mice were individually collected. 
The immunoglobulin pattern of the ascitic fluids 
and of immune serum was analyzed by microzone 
electrophoresis on cellulose acetate strips [18]. The 
binding activity and specificity of the antibodies 
secreted by the hybridomas was analyzed by radio- 
immunoassay (binding and inhibition experiments) 
[ 121 using AChR, RCM-AChR and T-AChR as the 
radiolabelled antigens. 
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3. Results of discussion 
In order to establish monoclonal antibodies with 
anti-AChR antibody activity, we fused spleen cells of 
AChR immunized mice with NSl non-secreting plas- 
macytoma line. Growth of hybrid cells was observed 
in 50% of the initial culture cells. In 20 out of 39 
independent cultures, anti-AChR antibody activity 
was detected by a radioimmunoassay with 1251-labelled 
AChR. These positive hybrid lines were further 
propagated invitro and in vivo, in the form of ascitic 
tumors. 
The immunoglobulins secreted by many of the 
hybridomas displayed, by microzone lectrophoresis, 
one sharp monoclonal band characteristic for each 
hybrid line, in contrast o the broad continuous 
immunoglobulin region observed upon electrophoresis 
of immune serum. The monoclonal immunoglobulin 
pattern of two representative hybrid lines is depicted 
in fig. 1, in comparison with the pattern of anti-AChR 
immune serum. The immunoglobulin pattern and 
Fig.1. Microzone electrophoresis in barbital buffer (pH 8.6) 
on cellulose-acetate strips of mouse anti-AChR serum and 
of ascitic fluid 1.4 and ascitic fluid 1.26. 
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antibody activity in the positive hybridomas were 
stable during all transfer cycles. 
For immunochemical analysis of the AChR deter- 
minants which are recognized by the various 
monoclonal antibody preparations, we have compared 
their activity towards the homologous antigen AChR 
with their activity towards two other receptor deriva- 
tives, RCM-AChR and T-AChR. RCM-AChR, which is 
a denatured AChR preparation obtained by reduction 
and carboxymethylation i  6 M guanidine-HCl, was 
shown to be devoid of pharmacological acetylcholine 
receptor activity [ 121. It crossreacts with intact 
AChR but does not induce myasthenic symptoms 
upon immunization [ 121. Moreover, RCM-AChR was 
shown to have suppressive effect on EAMG [ 191. On 
the other hand, T-AChR obtained following tryptic 
digestion of AChR retains the pharmacologic and 
myasthenic activity of intact purified AChR [ 131. As 
can be seen in table 1, anti-AChR sera from mice 
immunized with AChR contain antibodies binding to 
both RCM-AChR and T-AChR whereas, the antibodies 
produced by the hybridomas bound selectively only 
one of these antigens. The titration of two representa- 
tive ascitic fluids (AF 1.4 and AF 1.26) and of an 
immune serum with AChR, RCM-AChR and T-AChR 
is depicted in fig.2. Restricted ifferential specificity 
of the ascitic fluids’ antibodies i  demonstrated also 
in inhibition experiments (fIg.3). For instance, the 
binding of 1251-labelled AChR to AF 1.26 is inhibited 
by RCM-AChR and not by T-AChR whereas the 
binding to AF 1.4 is inhibited by T-AChR and not by 
RCM-AChR (fig.3B,C). Notably, sera from immunized 
mice contain heterogeneous mixture of antibodies 
among which the anti-RCM-AChR antibody popula- 
tion appears to be a minor component (Fig.3A). The 
ability to select preferentially for one specificity, 
even a minor one, is one of the advantages offered by 
the lymphocyte hybridization method. 
Since the original antibody forming cells were 
obtained from animals immunized with a detergent- 
solubllized AChR, it was of interest o check whether 
the hybridomas’ antibodies recognize the receptor in 
its natural membraneous form as present in situ. To 
study this, we tested the binding activity of the anti- 
bodies with AChR-rich membrane fragments [20] 
isolated from Torpedo electric organ, and specifically 
labelled with ‘251-labelled cu-bungarotoxin. All the 
hybridomas’ antibodies were found to bind this 
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Table 1 
Antibody titers in ascitic fluids (AF) 
Sample Antibody titera towards 
AChR RCM-AChR T-AChR 
AF 1.3 
AF 1.4 
AF 1.15 
AF 1.20 
AF 1.24 
AF 1.26 
AF 1.32 
AF 1.34 
AF 1.39 
Immune serum 
(pool) 
1.6 x lo-’ M 
1.0 x lo-* M 
1.0 x 1O-9 M 
1.4 x lo-’ M 
1.6 x 1O-6 M 
2.0 x lo-’ M 
1.4 x 10-s M 
1.6 x 1O-6 M 
3.1 x lo-’ M 
9.0 x lo-’ M 
0 4.0 X 10“ M 
0 1.3 x 1O-5 M 
0 1.0 x lo-* M 
0 2.0 x 1O-6 M 
0 2.0 x 1O-6 M 
4.0 X IO-’ M 0 
0 1.8 X lo-’ M 
4.0 X 1O-6 M 0 
8.0 X lo-’ M 0 
5.3 X lo-’ M 4.0 x lo-’ M 
a Antibody titers were determined by radioimmunoassay using goat anti-mouse 
Fab for precipitating the Ab-Ag complexes 
Titers are expressed as moles of antigen precipitated per litre of serum 
bungarotoxin-labelled membrane bound receptor. 
This finding indicates that the antibodies secreted by 
the hybridomas are directed against antigenic deter- 
minants exposed also on the membrane-bound 
receptor, which make these antibodies suitable for 
in vivo studies. When tested with detergent-solubi- 
lized AChR, all the antibodies demonstrated similar 
titer when analyzed either with ‘“I-labelled AChR or 
with 12sI-labelled a-bungarotoxin-AChR complex. 
This suggest hat none of these hybridomas produced 
antibodies against the bungarotoxin binding site of 
the receptor. Gomez et al. [21] have recently 
described one monoclonal hybridoma, originating 
from AChR immune rat cells, with specificity towards 
the bungarotoxin binding site. 
Our findings suggest hat some of the hybridomas 
secret antibodies which recognize selectively confor- 
mational antigenic determinants [22] of the acetyl- 
choline receptor, which are present in the trypsinated 
receptor and are absent in the denatured receptor. 
The myasthenic activity of the receptor molecule 
Antibody (dilution 1 
0.25 2.5 25 250 2yx) 2.5 25 250 2X., 2.5 25 250 25W 
Inhibitor Added ( ng 1 
Fig.2. Antibody specificity of ascitic fluids: binding experi- Fig.3. Antibody specificity of ascitic fluids: inhibition experi- 
ments. Binding of “‘I-labelled AChR (-) RCM-AChR ments. Inhibition of the binding of ‘asI-labelled AChR to: 
(----------)andT-AChR( . . . . . . . . . .) to: (A) C57BL/6J anti- (A)C57BL/6J anti-AChR serum;(B) AF 1.4; (C) AF 1.26 by 
AChR serum;(B) AF 1.4; (C) AF 1.26. AChR(-_),RCM-AChR(----------)andT-AChR( . . . . . . . . . . . . )
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residues within this group of determinants, Thus it 
may be expected that antibodies directed against 
these specificities may have pathological effect asso- 
ciated with myasthenic activity. On the other hand, 
other hyb~domas secret ~tibodies which recognize 
selectively RCM-AChR, which expresses the sequential 
antigenic determinants of the receptor molecule 
[ 12,221. Such antibodies are probably not associated 
with any myasthenic activity and may even have a 
preventive or therapeutic activity [21]. The classifica- 
tion of the specificity of the various antibodies may be 
further assessed by using additional reagents and frag- 
ments of the receptor, represent~g defmed antigenic 
regions. 
Thus, monospeciflc antibodies appear to be a use- 
ful tool for structural and functional analysis of AChR; 
they may help to defme the sites involved in the various 
biological activities related to AChR and to localize 
the various ubunits in relation to the cell membrane. 
Moreover, they may enable the elucidation of the role 
of antibodies of defined specificity, in regulating the 
immune response to AChR and the disease resulting 
from it. 
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